H.C. Wainwright lowered the firm’s price target on Outlook Therapeutics to $1.50 from $2 and keeps a Buy rating on the shares. The analyst cites a greater issuance of shares from the financing for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on OTLK:
- Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Outlook Therapeutics doses first subject in NORSE EIGHT trial
- Outlook Therapeutics® Doses First Subject in NORSE EIGHT
- Biotech Alert: Searches spiking for these stocks today
